Epidemiology, laboratory detection, and therapy of penicillin-resistant Streptococcal infections

Diagnostic Microbiology and Infectious Disease

Volumn 31, Issue 3, 1998, Pages 453-459

  Jones, Ronald N ^a   Wilson, Walter R ^b  

^a UNIVERSITY OF IOWA   (United States)

^b MAYO CLINIC COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFPIROME; PENICILLIN G;

ALPHA HEMOLYTIC STREPTOCOCCUS; BACTERICIDAL ACTIVITY; CONFERENCE PAPER; INFECTION RISK; NONHUMAN; PRIORITY JOURNAL; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE;

ANTI-BACTERIAL AGENTS; HUMANS; INCIDENCE; LABORATORY TECHNIQUES AND PROCEDURES; MICROBIAL SENSITIVITY TESTS; PENICILLIN RESISTANCE; PREVALENCE; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS; UNITED STATES;

EID: 0031798412     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0732-8893(98)00039-X     Document Type: Conference Paper

References (37)

1. Alcaide F., Linares J., Pallares R., Carratala J., Benitez M.A., Gudiol F., Martin R. In vitro activities of 22 β-lactam antibiotics against penicillin-resistant and penicillin-susceptible viridans group streptococci isolated from blood. Antimicrob Agents Chemother. 39:1995;2243-2247.
2. Bajaksouzian S., Visalli M.A., Jacobs M.R., Appelbaum P.C. Antipneumococcal activities of cefpirome and cefotaxime, alone and in combination with vancomycin and teicoplanin, determined by checkerboard and time-kill methods. Antimicrob Agents Chemother. 40:1996;1973-1976.
3. Ballow C.H., Jones R.N., Johnson D.M., Deinhart J.A., Schentag J.J. Comparative in vitro assessment of sparfloxacin activity and spectrum using results from over 14,000 pathogens isolated at 190 medical centers in the USA. Diagn Microbiol Infect Dis. 29:1997;173-186.
4. Barcus V.A., Ghanekar K., Yeo M., Coffey T.J., Dowson C.G. Genetics of high level penicillin resistance in clinical isolates of Streptococcus pneumoniae. FEMS Microbiol Lett. 126:1995;299-303.
5. Brandt C.M., Rouse M.S., Tallan B.M., Wilson W.R., Steckelberg J.M. Failure of time-kill synergy studies using subinhibitory antimicrobial concentrations to predict in vivo antagonism of cephalosporin-rifampin combinations against Staphylococcus aureus. Antimicrob Agents Chemother. 38:1994;2191-2193.
6. Breimann R.F., Butler J.C., Tenover F.C., Elliott J.A., Facklam R.R. Emergence of drug-resistant pneumococcal infections in the United States. J Am Med Assoc. 271:1994;1831-1835.
7. Carbon C. Prospective randomised phase II study of i.v. cefpirome 1 g or 2 g in the treatment of hospitalized patients with different infections. J Antimicrob Chemother. 29:(Suppl A):1992;87-94.
8. Chalkley L., Schuster C., Potgieter E., Hakenbeck R. Relatedness between Streptococcus pneumoniae and viridans streptococci transfer of penicillin resistance determinants and immunologic similarities of penicillin-binding proteins . FEMS Microbiol Lett. 69:1991;35-42.
9. Cherubin C.E., Eng R.H.K., Norrby R., Modai J., Hambert G., Overturf G. Penetration of newer cephalosporins into cerebrospinal fluid. Rev Infect Dis. 11:1989;526-548.
10. Cormican M.G., Jones R.N. Emerging resistance to antimicrobial agents in Gram-positive bacteria, enterococci, staphylococci and non pneumococcal streptococci. Drugs. 51:(Suppl 1):1996;6-12.
11. Doern G.V., Brueggemann A., Holley H.P. Jr, Rauch A.M. Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995 results of a 30 center national surveillance study . Antimicrob Agents Chemother. 40:1996;1208-1213.
12. Doern G.V., Ferraro M.J., Brueggemann A.B., Ruoff K.L. Emergence of high rates of resistance among viridans group streptococci in the United States. Antimicrob Agents Chemother. 40:1996;891-894.
13. Dowson C.G., Hutchison A., Woodford N., Johnson A.P., George R.C., Spratt B.G. Penicillin-resistant viridans streptococci have obtained altered penicillin-binding protein genes from penicillin-resistant strains of Streptococcus pneumoniae. Proc Natl Acad Sci USA. 87:1990;5858-5862.
14. Ejstrud P., Hansen J.B., Andreasen D.A. Prophylaxis against pneumococcal infection after splenectomy a challenge for hospitals and primary care . Eur J Surg. 11:1997;867-874.
15. Fong I.W., Tomkins K.B. Penetration of ceftazidime into the cerebrospinal fluid of patients with and without evidence of meningeal inflammation. Antimicrob Agents Chemother. 26:1984;115-116.
16. Friedland I.R., Sultan E., Lehr K.H., Lenfant B. Concentrations of cefpirome in cerebrospinal fluid of children with bacterial meningitis after a single intravenous dose. Antimicrob Agents Chemother. 42:1998;199-201.
17. Gavalda J., Capdevila J.A., Almirante B., Otero J., Ruiz I., Laguarda M., Allende H., Crespo E., Pigrau C., Pahissa A. Treatment of experimental pneumonia due to penicillin-resistant Streptococcus pneumoniae in immunocompetent rats. Antimicrob Agents Chemother. 41:1997;795-801.
18. Guillemont D., Carbon C., Balkau B., Geslin P., Lecoeur H., Vauzelle-Kervroedan F., Bouvenot G., Eschwege E. Low dosage and long treatment duration of β-lactam risk factors for carriage of penicillin-resistant . Streptococcus pneumoniae. 1998;JAMA 279:365-JAMA 279:370.
19. Hakenbeck R., Ellerbrok H., Briese T., Handwerger S., Tomasz A. Penicillin-binding proteins of penicillin-susceptible and -resistant pneumococci immunological relatedness of altered proteins and changes in peptides carrying the (-lactam binding site) . Antimicrob Agents Chemother. 30:1986;553-558.
20. Hakenbeck R., Briese T., Chalkey L., Ellerbrok H., Kallioski R., Latorre C., Leinonen M., Martic C. Antigenic variation of penicillin-binding proteins from penicillin-resistant clinical strains of Streptococcus pneumoniae. J Infect Dis. 164:1991;313-319.
21. Jones R.N., Kehrberg E.N., Erwin M.E., Anderson S.C. Prevalence of important pathogens and antimicrobial activity of parenteral drugs at numerous centers in the United States. I. Study on the threat of emerging resistances Real or perceived . Diagn Microbiol Infect Dis. 19:1994;203-215.
22. Jones RN, Pfaller MA, Doern GV, Verhoff, Jones M, Sader HS, SENTRY Study Group (1997) Initial report of a longitudinal, international antimicrobial surveillance study (SENTRY): Alarming resistance rates in monitored sites (68 medical centers) in the USA, Canada, South America, and Europe, abstr. E-109. In: The 37th International Congress of Antimicrobial Agents and Chemotherapy, Toronto, Canada.
23. Jorgensen J.H., Doern G.V., Maher L.A., Howell A.W., Redding J.S. Antimicrobial resistance among respiratory isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae in the United States. Antimicrob Agents Chemother. 34:1990;2075-2080.
24. Klugman K., Goldstein F., Kohno S., Baquero F. The role of fourth-generation cephalosporins in the treatment of infections caused by penicillin-resistant streptococci. Clin Microbiol Infect. 3:(Suppl 1):1997;S48-S60.
25. Martinez-Beltran J., Canton R., Linares J. Multicentre comparative study on the antibacterial activity of FK-037, a new parenteral cephalosporin. Eur J Clin Microbiol Infect Dis. 14:1995;244-252.
26. Marton A., Major P. In vitro susceptibility of Streptococcus pneumoniae strains to nine β-lactam antibiotics and the killing kinetics of cephalosporins alone and in combination with vancomycin or gentamicin. Microb Drug Resist. 2:1996;361-369.
27. Mogi A., Nishi J.I., Yoshinaga M., Harada H., Narahara S., Kawakami K., Maruyama I. Increased prevalence of penicillin-resistant viridans group streptococci in Japanese children with upper respiratory infection treated by β-lactam agents and in those with oncohematologic diseases. Pediatr Infect Dis. 16:1997;1140-1144.
28. Performance standards for antimicrobial susceptibility testing: Approved standard M100-S8. 1998;NCCLS, Wayne, PA.
29. Owens N.J., French M.A., Nightingale C.H., Klinek J.J., Moskovitz B., Quintiliani R. Penetration of cefoperazone into the cerebrospinal fluid in patients undergoing myelography and its pharmacokinetics in critically ill patients. Curr Ther Res. 33:1983;513-523.
30. Pallares P., Linares J., Vadillo M., Cabellos C., Manresa F., Viladrich P.F., Martin R., Gudiol F. Resistance to penicillin and cephalosporins and mortality from severe pneumonoccal pneumonia in Barcelona, Spain. N Engl J Med. 333:1995;474-480.
31. Quinn J.P., DiVicenzo C.A., Lucks D.A., Luskin R.L., Shatzer K.L., Lerner S.A. Serious infections due to penicillin-resistant strains of viridans streptococci with altered penicillin-binding proteins. J Infect Dis. 157:1988;764-769.
32. Smith A.M., Klugman K.P., Coffey T.J., Spratt B.G. Genetic diversity of penicillin-binding protein 2B and 2× genes from Streptococcus pneumoniae in South Africa. Antimicrob Agents Chemother. 37:1993;1938-1944.
33. Spika J.S., Facklam R.R., Plikaytis B.D., Oxtoby M.J. Antimicrobial resistance of Streptococcus pneumoniae in the United States, 1979-1987. J Infect Dis. 163:1991;1273-1278.
34. Tauber M.G., Hackbarth C.J., Scott K.G., Rusnak M.G., Sandre M.A. New cephalosporins cefotaxime, cefpimizole, BMY 28142, and HR 810 in experimental pneumococcal meningitis in rabbits. Antimicrob Agents Chemother. 27:1985;340-342.
35. Thornsberry C., Burton P.H., Vanderhoof B.H. Activity of penicillin and three third-generation cephalosporins against U.S. isolates of Streptococcus pneumoniae A 1995 surveillance study . Diagn Microbiol Infect Dis. 25:1996;89-95.
36. Washington J.A. A multicenter study of the antimicrobial susceptibility of community-acquired lower respiratory tract pathogens in the United States, 1992-1994; The Alexander Project. Diagn Microbiol Infect Dis. 25:1996;183-190.
37. Wolff M. Comparison of strategies using cefpirome and ceftazidime for empiric therapy of pneumonia in intensive care patients. Antimicrob Agents Chemother. 42:1998;28-36.